Reform of the pharmaceutical companies' levy on drug promotion expenses
Article 15 of the 2003 Social Security Financing Act refocuses the levy on reimbursable drug companies on sales representatives' pay, their travel costs and advertising expenses, with a €500,000 flat allowance, a 3% allowance on pay, 30% allowances for generics and orphan drugs, a four-band scale and an exemption below €15 million turnover.
Measure originators
No official estimate found for this measure.
Measure impact
Drug companies pay the levy on the new base for the first time for contributions due by 1 December 2003; small firms below €15m turnover are exempt.
Official references
Sources
Procedure timeline
Follow the progress of this fiscal measure through the different stages of the parliamentary procedure.
Administrative implementation
Entrée en vigueur de la mesure et mise en œuvre par l'administration
President of the Republic signature
Publication au Journal officiel
Possible referral to Constitutional Council
Décision de conformité / censure partielle
National Assembly has the final say
Si échec CMP
Debate and vote
Débat et vote en séance publique à l'Assemblée nationale, ou engagement de la responsabilité du Gouvernement (article 49.3)